Top > Health and Fitness 
Health and Fitness
| 11. |
RNCOS Releases a New Report- Market Potential for Hospital Services, Pharmaceuticals and Medical Dev
|
|
|
RNCOS has recently added a new Market Research Report titled, "Market Potential for Hospital Services, Pharmaceuticals and Medical Devices in US" to its report gallery. The US, with its healthcare spending crossing US$ 2.2 Trillion in 2007, represents the most important healthcare product and services market in the world. And according to “Market Potential for Hospital Services, Pharmaceuticals and Medical Devices in US”, the new research report from RNCOS, the potential and opportunities in this market are expected to increase several fold in the next five years.
This report provides factual insight supplemented with statistical overview on the past, present and future market. It studies the entire structure, composition and working of the US healthcare sector and describes the potential of hospital services, pharmaceuticals and medical devices in the market. This report discusses the demand, market size and future prospects of nearly every major sector, like cardiovascular, diabetes, musculoskeletal, oncology, wound care management, cosmetic surgery, dental health, and in vitro diagnostics, in the US healthcare market. It identifies key opportunities and roadblocks that will affect the future direction of the market.
“Market Potential for Hospital Services, Pharmaceuticals and Medical Devices in US” thus serves as a guide for healthcare service providers/drug manufactures/investors who are planning to enter the US healthcare market as it helps in identifying and analyzing market opportunities that will suit their business needs and profiles.
Key Findings of the Report
- Total healthcare spending in the US is expected to grow at a CAGR of 7% between 2007 and 2012.
- Around 43 Million people are expected to be above 65 years of age in the US by 2012, thereby increasing the prevalence of several chronic diseases.
- Around 122 Million Americans are expected to suffer from cardiovascular diseases by 2012, leading to direct expenses of over US$ 414 Billion.
- The US, with over 19 Million diabetics by 2012, is expected to fuel the growth of the diabetes drugs and monitoring devices market.
- Driven by target-based therapies with negligible side effects, the US oncology market is amongst the fastest growing sectors in the healthcare industry.
- The aging baby boomers, coupled with an increasing incidence of hip and knee fractures, are expected to strongly drive the musckoskeletal market.
- Driven by a need to look young and attractive, both surgical and non-surgical cosmetic procedures are becoming highly popular.
Key Issues & Facts Analyzed in the Report
- Evaluation of past, current and future market trends.
- Market evaluation by type of disease.
- Discussion on the major drivers of the healthcare market.
- Identification and evaluation of the opportunities created by the market.
- Analysis of major challenges for the market.
Research Methodology Used in the Report
Information Sources
Information has been sourced from books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to over 3000 paid databases.
Analysis Methods
RNCOS industry forecast and analysis is based on various macro- and microeconomic factors, sector and industry specific databases, and our in-house statistical and analytical model. This model takes into account the past and current trends in an economy, and more specifically in an industry, to bring out an objective market analysis.
Our industry experts study the relationship between various industry and economic variables to ensure the required accuracy and desired check on the quality of data and information given in the report.
For more information visit: http://www.rncos.com/Report/IM147.htm
Current Industry News: http://www.rncos.com/Blog/
Date Added: Dec 13, 2008 Hits: 0 Rating: 0.00 Votes: 0
|
|
Member Reviews |
 |
Visitor Ratings |
 |
Google PR |
 |
|
| 12. |
RNCOS Releases a New Report- Ukraine Pharma - New Opportunities for Growth
|
|
|
RNCOS has recently added a new Market Research Report titled, “Ukraine Pharma - New Opportunities for Growth” to its report gallery. According to the new research report, Ukraine promises to be one of the most lucrative pharmaceutical markets in the world. In 2007, the Ukrainian pharmaceutical market grew by nearly 21% to register revenues in excess of US$ 2 Billion. The market is characterized by an increasing proportion of imported and high-priced drugs. In 2007, the average unit price of drugs sold in Ukraine increased by nearly 20%, strongly pushing the value of pharmaceutical sales, despite a relatively ordinary growth in sales volume.
The future outlook of the industry also seems very positive as the market is expected to be driven by a number of reforms recently proposed by the government. Factors such as increasing penetration of health insurance and increasing disposable incomes of consumers will also fuel growth. The lack of effective price controls and high margins are also expected to lure foreign players in this market. The country’s unstable political environment, however, will be the biggest hurdle for investments. But overall, the market is expected to grow strongly, exceeding US$ 4.5 Billion in revenues by 2012.
This report gives an extensive and objective analysis on the pharmaceutical market of Ukraine. It investigates both the past and present trends in the market, with its main focus on the future trends shaping the industry. The study discusses the performance of both the retail and hospital segments of the pharmaceutical market in detail and based on various present and future indicators, analyzes the future of these segments. This report gives valuable information to manufacturers/investors planning to enter the Ukrainian pharmaceutical market.
The Report Provides Forecasts on
- Macroeconomic Indicators
- Healthcare Indicators
- Population & Demographics
- Disease Profiles
- Total Pharmaceutical Market
- Retail Pharmaceutical Market
- Hospital Pharmaceutical Market
Key Player Profiling
“Ukraine Pharma - New Opportunities for Growth” provides brief profiling on key players, both domestic and foreign, currently operating in the Ukraine pharmaceutical market. This section describes the revenues and growth of players in the total pharmaceutical market, retail market and hospital market. Performance of key drugs in various segments of the market has also been evaluated. Business profiles of top five players, Berlin Chemie, Sanofi Aventis, Novartis, Arterium and Darnitsa, have also been discussed in this report.
For more information visit: http://rncos.com/Report/IM161.htm
Current Industry News: http://www.rncos.com/Blog/
Date Added: Jan 23, 2009 Hits: 0 Rating: 0.00 Votes: 0
|
|
|
Member Reviews |
|
Visitor Ratings |
|
Google PR |
 |
|
| 13. |
Colonic Irrigation, Slough UK
|
|
|
Meet the expert’s in anatomy and physiology with considerable training and experience in a body-based complementary therapy other than colonic therapy. Expect the remarkably hygienic and clean shop center located at Slough UK.
For your emotional and spiritual ailments there are various massages, therapies and beauty treatments that you on all levels - mind, body and spirit can be treated on.
At Body Peace we provide a wide range of holistic complementary treatments. Body Peace is a well established modern Complementary and Alternative Medicine Clinic specializing in aspects of medicine, from Colon (colonic Irrigation) Hydrotherapy, Allergy/Intolerance testing, Body Detox, Homeopathy, Hypnotherapy(stopping smoking) Psychotherapy, series of health massages etc.. We are located in Maidenhead, Taplow, Berkshire, treatments are from 9.30a.m.-10p.m. 7 days a week.
Date Added: Jan 23, 2009 Hits: 0 Rating: 3.00 Votes: 1
|
|
|
Member Reviews |
|
Visitor Ratings |
 |
Google PR |
 |
|
| 14. |
Population Boom Bucking Up Saudi Arabian Healthcare Sector
|
|
|
Saudi Arab is amongst the world’s fastest growing healthcare markets, and the biggest factor spurring this growth is the rapidly expanding population of the country, according to “Saudi Arabian Healthcare Market Forecast to 2012”, a new research report by RNCOS.
The report finds that despite healthy investment in new bed installations, the rate of population growth has significantly outpaced the rate of bed growth from early 1990s to 2008, leading to a fall in the bed to population ratio from 2.55 beds per thousand population to the present 2.36 beds per thousand population.
Currently, the country is witnessing maximum growth in the population segment at or above 65 years of age. The report forecasts this population segment to expand by 15% between 2008 and 2012, outpacing the 10% increase in the total population. With increasing aging population, the prevalence of a number of chronic diseases such as obesity, diabetes, cardiovascular and dementia will grow exponentially in future. This will significantly push the demand for hospital services, pharmaceuticals and medical devices in future.
Apart from the shortage of beds, the fast expanding population will also create a shortage of healthcare professionals in the country. Most of the healthcare professionals in the country are foreign nationals with high turnover rates. As a result, the government has taken a number of steps to improve its medical education infrastructure. However, the number of medical graduates passing out in the foreseeable future is not likely to match the demand emerging from the ever-increasing population. This will open up big opportunities for the education services market in Saudi Arab.
“Saudi Arabian Healthcare Market Forecast to 2012” gives an extensive and objective analysis on the Saudi Arab healthcare market. It has segmented the healthcare industry under the heads hospital services, pharmaceuticals and medical devices. Analysis as well as statistics on these segments regarding the market size, demand, supply, segmentation and key players has been given in this report.
An analysis on the future directions, supplemented with both facts and figures has also been done by the report. Thus, the research study serves as a useful guide for healthcare companies, government officials, consultants and investors who are planning to foray into the Saudi Arab healthcare market.
Date Added: Mar 23, 2009 Hits: 0 Rating: 0.00 Votes: 0
|
|
|
Member Reviews |
|
Visitor Ratings |
|
Google PR |
 |
|
| 15. |
RNCOS Releases a New Report- Booming Clinical Trials Market in India
|
|
|
RNCOS has recently added a new Market Research Report titled, “Booming Clinical Trials Market in India” to its report gallery. According to the new RNCOS report, India promises to be one of the hottest destinations for conducting global clinical research, owing to a huge patient pool representing both chronic and infectious diseases, easy recruitment of patients, and high cost savings.
India presently occupies a very small pie of the global opportunity. The total number of clinical trials in India stood at 221 in 2007, which equates to less than 2% of the global clinical trials. With all major pharmaceutical/biotech companies and CROs establishing their presence in India, the number of clinical trials in the country is expected to grow several folds in the next five years. The country is projected to conduct nearly 5% of the global clinical trials by 2012. However, to achieve its goal of becoming a global hub of clinical trials, the country has to overcome challenges like unethical trials, delay in trial approval, inappropriate protection of clinical data, and lack of Good Clinical Practice (GCP) certified sites and investigators. Surging clinical trials market in India will create enormous opportunities for a number of associated industries, including IVD market, education sector and clinical data management.
“Booming Clinical Trials Market in India” gives an extensive and objective analysis on the Indian clinical trials market. It investigates the advantages/disadvantages India has in becoming a global clinical trials hub. The report exhaustively evaluates and compares the key factors that drug companies and CROs look before outsourcing clinical trials to a country. These include parameters such as patient pool, regulatory environment, cost, infrastructure, human resources and past performance in conducting clinical trials. Thus, this analytical study serves as a useful guide for drug manufacturers, CROs, consultants and investors who are planning to enter the Indian clinical trials market.
Our report provides forecasts on
- Size of global clinical research outsourcing market
- Size of Indian clinical research outsourcing market
- Number of clinical trials in India
- Number of patients expected to participate in clinical trials in India
- Clinical trials infrastructure and professionals in India
- Healthcare indicators in India
Key questions answered in the report
- Why are drug manufacturers outsourcing clinical trials?
- Where and how many clinical trials are being outsourced?
- Where dose India stand in the global clinical trials market?
- How big is the clinical trials opportunity in India?
- How much does it cost on hiring personnel for various clinical research processes, rent and utilities in India as compared to other countries?
- How does clinical trials infrastructure and staff in India vary from other countries?
- What are various government regulations/guidelines for conducting clinical trials in India?
- What are the Future trends predicted to shape the clinical trials market in India?
- How is the clinical trials market impacting associated industries?
Key players analyzed in the report
This section provides business overview on prominent players in the Indian clinical research market like Syngene International Ltd, Quintiles Research (India) Private Limited, Lambda Therapeutic Research Ltd, Vimta Labs Limited and Veeda Clinical Research - India.
For more information visit: http://www.rncos.com/Report/IM564.htm
Current Industry News: http://www.rncos.com/Blog/
Date Added: Mar 23, 2009 Hits: 0 Rating: 0.00 Votes: 0
|
|
|
Member Reviews |
|
Visitor Ratings |
|
Google PR |
 |
|
| 16. |
Time Management Skills to Help You Pass Your CPC Exam
|
|
|
You've got 5 hours for your CPC exam - but should you tackle that heart catch coding scenario or skip it? Join us at an upcoming CPC Training Camp, and gain time management skills to help you know for sure.
Don't waste time and money on CPC exam prep courses that offer non-practical information. CPC Training Camps have been designed to provide you with only the information you need in order to successfully pass your CPC exam.
And that's not all! 3 days are all it takes to prepare. During your 3 days of CPC exam preparation, you'll learn exactly what the CPC exam expects you to know, what format you can expect, and what you can skip. Your AAPC approved instructor will guide you as you tackle and review practice questions so that you're prepared for the real thing. Overall, you'll get a first-rate, insider's guide to passing CPC certification exam that you won't find anywhere else!
Here's a little preview of what you'll learn at your 3-Day CPC Training Camp:
•CPC Exam-Taking Tips from the Pros
•What the CPC Exam Wants You to Know About ICD-9 CM
•Are You A Modifier Master?
•Insider's Guide to the Integumentary Questions
•Musculoskeletal, Cardiovascular & Respiratory Surgery Review
•Down There: The 40,000 and 50,000 Series
•Get Set for 60,000
•Anesthesia Coding Crash Course
•What the CPC Exam Wants You to Know about E/M?
•Radiology, Path/Lab, Medicine Pointer You Can’t Afford to Miss
To reserve your spot at your nearest CPC Training Camp, call 688-458-2962.
Know more about CPC Exams at "http://www.codingcert.com"
"http://codingcertificationtraining.wordpress.com/
Date Added: Mar 27, 2009 Hits: 0 Rating: 0.00 Votes: 0
|
|
|
Member Reviews |
|
Visitor Ratings |
|
Google PR |
 |
|
| 17. |
RNCOS Releases a New Report- Saudi Arabian Healthcare Market Forecast to 2012
|
|
|
RNCOS has recently added a new Market Research Report titled, “Saudi Arabian Healthcare Market Forecast to 2012” to its report gallery. According to the new RNCOS report, the Saudi Arabian healthcare market is witnessing rapid growth and will continue to expand exponentially in future. The country’s rapidly increasing population, due to which demand is outpacing supply, can be regarded as the main push for the market. And as the incidences of a number of lifestyle diseases, such as obesity, diabetes and hypertension, in the country amongst the highest in the world, these will significantly boost the healthcare spending in future.
Government plays a central role in providing healthcare services in the kingdom, accounting for around 75% of the total healthcare spending in the country. The government accounted for 67% of the total hospitals and 77% of the total hospital beds in the country in 2006. The government expenditure on healthcare, however, is increasing faster than its total income; as a result, government may resort to cost cutting measures in future.
The report says that due to increasing pressure on the public healthcare system, the government is rapidly promoting the involvement of private healthcare in the country. So big investment will be seen from the private sector in the forecasted period, and according to our estimates, the private sector will account for 62% for all new beds installed during 2006-2012.
However, slump in crude oil prices due to economic recession can hit the nation’s economy. But the fast diversification of the country’s economy into other sectors will provide it a buffer against the severe impact of economic turmoil. Despite some challenges such as shortage of skilled workers, dependency on oil and bureaucratic issues, the market’s future will remain bright with all three sectors - hospital services, pharmaceuticals and medicals devices - expected to show sustained growth.
“Saudi Arabian Healthcare Market Forecast to 2012” gives an extensive and objective analysis on the Saudi Arabian healthcare market. It has segmented the healthcare industry into hospital services, pharmaceuticals and medical devices. It provides analytical and statistical information on these segments, including their market size, demand, supply, segmentation and key players. It also features an analysis on the future directions, supplemented with facts and figures. Thus, the report serves as a useful guide for healthcare companies, government officials, consultants and investors who are planning to enter the Saudi Arab healthcare market.
Our report provides forecast on
- Macroeconomic indicators
- Demographic and healthcare indicators
- Healthcare spending
- Demand for hospital beds
- Pharmaceutical market
- Medical devices market
Key questions answered in the report
- Which factors are driving the Saudi Arabia healthcare market?
- What is the past and present size of the healthcare market?
- What is the role of public and private sectors in providing healthcare?
- What is the total supply and demand for hospital services in Saudi Arab?
- What will be the demand, investment and infrastructure scenario in the hospital services market?
- What is the total size and future outlook of the pharmaceutical market?
- Who are the key players operating in the pharmaceutical market?
- What is the total size and future outlook of the medical devices market?
- What are the key challenges faced by the Saudi Arabia healthcare market?
For more information visit: http://www.rncos.com/Report/IM173.htm
Current Industry News: http://www.rncos.com/Blog/
Date Added: Mar 27, 2009 Hits: 0 Rating: 0.00 Votes: 0
|
|
|
Member Reviews |
|
Visitor Ratings |
|
Google PR |
 |
|
| 18. |
RNCOS Releases a New Report- Japanese Generic Market Forecast to 2013
|
|
|
According to “Japanese Generic Market Forecast to 2013”, a new research report by RNCOS, Japan promises to be one of the most lucrative generic markets in the world. Between 2005 and 2008, the Japanese generics market grew at a CAGR of around 7.5% to register ¥ 333 Billion (US$ 3.5 Billion) in revenue.
The Japanese market is characterized by a strong support by the government, which in a desperate bid to limit its healthcare costs, is introducing a number of generic-friendly policies. Other factors such as a large number of patent expiries and the largely un-penetrated nature of the market are also contributing towards the market growth.
The generic market is presently dominated by domestic manufacturers, with the top six manufacturers accounting for 56% of the total market in 2007. But opening up of the market and introduction of a number of generic-friendly reforms is attracting a number of foreign players in the market.
Despite such a big opportunity for future, the market also has a number challenges to deal with. Generic drugs are still regarded as cheap, low quality alternatives of branded drugs. Thus, both physicians and patients are skeptic regarding their safety and efficacy. A number of awareness and educational programs, however, are expected to increase their awareness in future.
Despite these challenges, our forecast models suggest that the generic drugs market will grow at a CAGR of around 8.8% between 2009 and 2013.
The report gives an extensive and objective analysis on the generic market in Japan. It investigates both the past and present trends in the generic market, but its focus is on the future trends shaping the industry. The report also investigates the performance of various players in the Japanese pharmaceutical and generic markets, and analyzes the competitive landscape in these markets. Based on various present and future indicators, the future scenario of the market has also been analyzed.
Key questions answered in the report
- What is the size and penetration level of the Japanese generic market?
- How is the Japanese generic market different from other developed markets?
- What are the key drivers and challenges for the generic market?
- What is the role of government in the market?
- What is the viewpoint of patients and physicians on generic drugs?
- What is the future outlook of the drug market?
- Who are the key players operating in the Japanese generic market?
Key players operating in Japanese generic market
This report features the key players currently operating in the Japanese pharmaceutical and generic markets. This section describes market shares and growth of key pharmaceutical and generic players in Japan. Profiles of the top six generic manufacturers have been provided in the report.
For more information visit: http://www.rncos.com/Report/IM170.htm
Current Industry News: http://www.rncos.com/Blog/
Date Added: Apr 15, 2009 Hits: 0 Rating: 0.00 Votes: 0
|
|
|
Member Reviews |
|
Visitor Ratings |
|
Google PR |
 |
|
| 19. |
Japanese Government Promoting Generics to Ceil Surging Healthcare Cost
|
|
|
According to the report “Japanese Generic Market Forecast to 2013”, the Japanese government spent around 7% of the country’s GDP on healthcare services in 2008, and this percentage is increasing at an alarming rate due to surging therapy cost with advancing technology. It’s expected that if serious cost containment measures are not taken by the government, then the total funding gap would reach around US$ 202 Billion by 2020 and 465 Billion by 2035, jeopardizing the entire healthcare structure.
Pharmaceuticals account for a major share in the government healthcare expenditure. As pharmaceutical drugs are expensive, the government encourages the sales and investment in the generic market. This led to the introduction of a step-by-step policy to boost generic sales from the early years of this decade, including subsidies for doctors who merely explain the benefits of generic substitutes. Pharmacists are also receiving government cash for dispensing non-patented medicines.
In an effort to encourage the use of generic drugs, the government is also expected to create a system in which patients opting for previously patented medications will have to shoulder a larger financial burden if an equally effective generic version exists. Under the new system, insurance coverage of drugs will also be decided by assessing the average price of existing generic treatments if both original and generic versions are available.
Other factors such as new regulations for biogenerics, introduction of a faster system for approving new drug applications, and removal of the obligation to manufacture locally are also expected to push the Japanese generic drugs market in future. The last change is particularly a significant one since it means that pharma companies can market their drugs in Japan without having to operate their own production facilities.
Driven by these factors, our forecast models expect the generic market to grow at a CAGR of nearly 9% between 2008 and 2013.
“Japanese Generic Market Forecast to 2013” gives an extensive and objective analysis on the generic market in Japan. It investigates both the past and present trends in the generic market, with its focus on the future trends shaping the industry. It also features the performance of various players in Japanese pharmaceutical and generic markets and analyzes the competitive landscape of the markets. Based on various present and future indicators, the future scenario of the market has also been analyzed.
For more information visit: http://www.rncos.com/Report/IM170.htm
Current Industry News: http://www.rncos.com/Blog/
Date Added: Apr 15, 2009 Hits: 0 Rating: 0.00 Votes: 0
|
|
|
Member Reviews |
|
Visitor Ratings |
|
Google PR |
 |
|
| 20. |
US Musckoloskeletal Device & Implant Market to Grow 11.8% by 2012
|
|
|
The US musckoloskeletal device and implant market was valued at more than US$ 20 Billion in 2008, making up for over 50% of the global market for such devices, according to “Market Potential for Hospital Services, Pharmaceuticals and Medical Devices in US”, a new research report from RNCOS. The market is projected to see a blistering CAGR growth of 11.8% through 2012.
The reconstructive surgery segment, representing 33.5% of the musculoskeletal device and implant market, is expected to be the key booster to the US musculoskeletal device & implant market in the next four years, with Spinal (30.7%) and Fixation (16.0%) playing secondary role in the growth, anticipates the report.
Re-constructive joint implants are likely to continue to represent the largest segment in the reconstructive surgery field primarily due to rising demand for more procedures by increasing elderly population. The positive outlook for joint implants segment is based on figures of 2007 when nearly 663,000 knee replacement procedures and 251,000 hip replacement procedures were successfully performed, according to the report. Further, the number of both hip and knee replacement procedures is expected to surge sharply by 2012, with increasing incidents of knee and hip fractures and decreasing relevance of patients’ age profile. Patients are opting for such procedures at a much younger age now while earlier they were chosen at much older age.
“Market Potential for Hospital Services, Pharmaceuticals and Medical Devices in US” discusses the past, current and future market scenario by providing factual details along with quality statistical data. The report gives insight into the structure, composition and working of the US healthcare sector and discusses hospital services, pharmaceuticals and medical devices available in the market.
Besides, it contains information on demand, market size and future prospects of all major US healthcare segments such as cardiovascular, in vitro diagnostics, diabetes, dental health, musculoskeletal, cosmetic surgery, oncology and wound care management. It will help the clients to understand key opportunities and challenges that will guide the market in future.
The research study provides forecast on factors like cancer surgery market, biotechnology-based cancer drug market, wound care product market, osteoporosis & low bone mass patients, hip replacement procedures, knee replacement procedures and cardiovascular diseases, and stroke expenditure by type.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM147.htm
Check DISCOUNTED REPORTS on http://www.rncos.com
About RNCOS:
RNCOS, incorporated in the year 2002, is an industry research firm. We are a team of industry experts who analyze data collected from credible sources. We provide industry insights and analysis that helps corporations to take timely and accurate business decision in today's globally competitive environment.
Date Added: Apr 15, 2009 Hits: 0 Rating: 0.00 Votes: 0
|
|
|
Member Reviews |
|
Visitor Ratings |
|
Google PR |
 |
|
|
Editors:
hydrotec
|
